- 13 Ways To Know If The Government Is Reading Your EmailPosted 29 mins ago
- Video: Piers Morgan Says Obama is Borderline Tyrannical: ‘Now I See U.S. Government Tyranny’Posted 3 days ago
- FAMILIES OF DECEASED SEAL TEAM 6 MEMBERS ARE MAKING SERIOUS ALLEGATIONS AGAINST THE GOVERNMENTPosted 14 days ago
- European Commission to Criminalize Nearly all Seeds and Plants not Registered with GovernmentPosted 15 days ago
- After the Tragedy in Boston, More Government Surveillance is Not the AnswerPosted 16 days ago
- Video: Obama To Ohio State Grads-Reject Voices That Warn About Government TyrannyPosted 16 days ago
- AMERICANS FEAR GOVERNMENT MORE THAN TERRORPosted 24 days ago
- The Art of Catching Government False Flags in Real TimePosted 24 days ago
- SECRET GOVERNMENT DOCUMENTS REVEAL VACCINES TO BE A TOTAL HOAXPosted 30 days ago
- WIKILEAKS: THE GOVERNMENT IS SPYING ON YOU THROUGH YOUR IPHONEPosted 40 days ago
Johnson & Johnson Issues Weak Earnings Guidance For 2013 (JNJ)
Johnson & Johnson just reported earnings for the fourth quarter of 2012.
The market is focused on the weak earnings guidance the company issued for 2013, in the range of $ 5.35-5.45 per share, below analysts’ estimates of $ 5.49.
Revenues in Q4 were also softer than expected at $ 17.56 billion versus expectations of $ 17.65 billion.
However, the company also beat analysts’ estimates on Q4 2012 earnings, which came in at $ 1.19 per share versus expectations of $ 1.16 per share.
The stock is down slightly in pre-market trading.
Below is the full text from the release:
NEW BRUNSWICK, N.J., Jan. 22, 2013 /PRNewswire/ – Johnson & Johnson (JNJ) today announced sales of $ 17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of currency was 1.3%. Domestic sales increased 6.8%, while international sales increased 8.9%, reflecting operational growth of 11.2% and a negative currency impact of 2.3%. Sales for the fourth quarter of 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 5.6% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business. Worldwide sales for the full-year 2012 were $ 67.2 billion, an increase of 3.4% versus 2011. Operational sales increased 6.1% and the negative impact of currency was 2.7%. Domestic sales increased 3.2%, while international sales increased 3.5%, reflecting operational growth of 8.4% and a negative currency impact of 4.9%. Sales for the full-year 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 3.1% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
Net earnings and diluted earnings per share for the fourth quarter of 2012 were $ 2.6 billion and $ 0.91, respectively.** Fourth-quarter 2012 net earnings included after-tax special items of $ 0.8 billion, primarily related to an increase in the litigation accrual and program costs associated with the DePuy ASR™ Hip, in-process research and development, and integration and transaction costs related to the acquisition of Synthes, Inc.
Fourth-quarter 2011 net earnings reflect after-tax special items of $ 2.9 billion as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items for both periods, net earnings for the current quarter were $ 3.4 billion and diluted earnings per share were $ 1.19, representing increases of 7.9% and 5.3%, respectively, as compared to the same period in 2011.*
Net earnings and diluted earnings per share for the full-year 2012 were $ 10.9 billion and $ 3.86, respectively.** Full-year net earnings reflect after-tax special items of $ 3.5 billion in 2012 and $ 4.2 billion in 2011 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year 2012 were $ 14.3 billion and diluted earnings per share were $ 5.10, representing increases of 3.4% and 2.0%, respectively, as compared with the full year of 2011.*
“Johnson & Johnson delivered solid results in 2012 reflecting continued sales momentum in many parts of our business driven by our focus on delivering meaningful innovation in health care to patients and customers. Our results included strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies,” said Alex Gorsky, Chairman and Chief Executive Officer. ”In addition, we continued to make important investments building strategic partnerships and in advancing our pipeline, positioning us well for delivering sustainable growth as we enter 2013. I would also like to thank our talented colleagues at Johnson & Johnson for their extraordinary achievements in helping advance health and well-being for patients and customers around the world.”
The Company announced earnings guidance for full-year 2013 of $ 5.35 to $ 5.45 per share, which excludes the impact of special items.
Worldwide Consumer sales of $ 14.4 billion for the full-year 2012 represented a decrease of 2.9% versus the prior year, consisting of an operational increase of 0.5% and a negative impact from currency of 3.4%. Domestic sales decreased 2.0%; international sales decreased 3.4%, which reflected an operational increase of 1.9% and a negative currency impact of 5.3%.
Positive contributors to operational results were sales of upper respiratory over-the-counter products; international sales of LISTERINE® oral care products; and U.S. sales of NEUTROGENA® skin care products.
Worldwide Pharmaceutical sales of $ 25.4 billion for the full-year 2012 represented an increase of 4.0% versus the prior year with an operational increase of 6.8% and a negative impact from currency of 2.8%. Domestic sales increased 0.3%; international sales increased 7.9%, which reflected an operational increase of 13.6% and a negative currency impact of 5.7%.
Primary contributors to operational sales growth were REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases; VELCADE® (bortezomib), a treatment for multiple myeloma; PREZISTA® (darunavir), a treatment for HIV; and a number of recently launched products.
The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; international sales of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; XARELTO® (rivaroxaban), an oral anticoagulant; and SIMPONI® (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Sales results were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections and the manufacturing suspension at a third party supplier for DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.
During the quarter, the U.S. Food and Drug Administration (FDA) granted accelerated approval for SIRTURO™ (bedaquiline) tablets for the treatment of pulmonary multi-drug resistant tuberculosis as part of combination therapy in adults. The FDA and the European Commission also approved an expanded indication for ZYTIGA® (abiraterone acetate), in combination with prednisone, allowing for the use before chemotherapy in the treatment of metastatic castration-resistant disease.
In November, the FDA approved XARELTO® (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. In addition, the FDA approved a new 800mg tablet of PREZISTA® (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations.
Also during the quarter, a New Drug Application was submitted to the FDA seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. Additional submissions included a supplemental Biologics License Application to the FDA and a Type II Variation to the European Medicines Agency requesting approval of STELARA® (ustekinumab) for the treatment of adult patients with active psoriatic arthritis.
Worldwide Medical Devices and Diagnostics sales of $ 27.4 billion for the full-year 2012 represented an increase of 6.4% versus the prior year with an operational increase of 8.7% and a negative impact from currency of 2.3%. Domestic sales increased 8.7%; international sales increased 4.5%, which reflected an operational increase of 8.6% and a negative currency impact of 4.1%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 7.9% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
Primary contributors to operational growth were sales from the recently completed acquisition of Synthes, Inc. in the Orthopaedics business; a number of products in the Specialty Surgery business; Biosense Webster’s electrophysiology products in the Cardiovascular Care business; and Vistakon’s disposable contact lenses.
During the quarter, the FDA approved EVARREST™ Fibrin Sealant Patch, a novel product that rapidly and reliably aids in stopping problematic bleeding during surgery. The FDA also approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery and/or the proximal popliteal artery.
Gisele Bündchen for BLK DNM Campaign by Johan Lindeberg
Denim label BLK DNM has just released it’s latest ‘Wild’...
- Posted 3 hours ago
A.P.C. x Eastpak Capsule Collection
For Fall/Winter 2013, Eastpak has chosen French brand A.P.C. as...
- Posted 7 hours ago
WITH NEW MINI-SATELLITES, SPECIAL OPS TAKES ITS MANHUNTS INTO SPACE
In September, the U.S. government will fire into orbit...
- Posted 14 hours ago
POWER TRIP: COP THREATENS TO BEAT CITIZEN AND PLANT COCAINE ON HIM
Our Secret House
- Posted 1 day ago
FAMILIES OF DECEASED SEAL TEAM 6 MEMBERS ARE MAKING SERIOUS ALLEGATIONS AGAINST THE GOVERNMENT
Three families of Navy SEAL Team VI Special Forces...
- Posted 14 days ago